Objectives To determine association, and predictive ability, of first trimester maternal serum pregnancy associated plasma protein A (PAPP-A) with adverse pregnancy outcomes.
INTRODUCTION
Adverse pregnancy outcomes [stillbirth, preterm birth (PTB), small for gestational age (SGA) and hypertensive disorders of pregnancy] have a major psychological impact for the family as well as an increased cost for the healthcare system. Accurate methods of predicting these outcomes would allow health professionals to provide increased surveillance and offer optimum management, which could possibly improve the outcome of the pregnancy.
Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein produced by syncytial trophoblast, which cleaves insulin-like growth factor binding protein 4 and is a positive regulator of insulin-like growth factors. 1 Biochemical measurement of placental derived factors has been suggested as a means to improve fetal and maternal outcome of pregnancy. Previous studies have tested the hypothesis that low maternal serum levels of PAPP-A in the first trimester can predict adverse pregnancy outcomes associated with poor placental function. [2] [3] [4] [5] [6] The recently published Royal College of Obstetricians and Gynaecologists Green top Guidelines assessed all the available evidence prior to their publication in 2013 and recommended that in women with a serum PAPP-A <0.415 multiples of the median (MoM) (5th centile) in the first trimester receive increased ultrasound surveillance for growth disorders. 7 This recommendation was based on a previous systematic review by our group in 2008 assessing Down syndrome markers to predict pre-eclampsia and SGA. 8 This review included only 16 studies, did not assess all outcomes and did not distinguish between prognosis and prediction. 8 In 2010, first trimester combined screening was routinely introduced in the UK as the recommended screening for Down syndrome. 9 This test involves assay of PAPP-A between 10 and 13 + 6 weeks. Thus, since this time, there has been a substantial increase in the number of published articles related to this placental analyte and therefore a need to systematically review this evidence.
When assessing a biomarker, it is important to assess whether there is any prognostic association between the 'analyte' and outcomes of interest before considering the predictive ability of the biomarker to predict the outcome of interest in an individual. 10 It is also important to determine whether PAPP-A has a true prognostic ability for adverse pregnancy outcome to determine its use in pregnancy surveillance with newer methods of aneuploidy screening such as non-invasive prenatal testing with cell free fetal DNA. The aim of this systematic review and meta-analysis is to improve our understanding of the association between first trimester maternal serum PAPP-A levels and pregnancy outcomes and where appropriate to evaluate the predictive ability for adverse pregnancy outcomes.
METHODS
A protocol-driven systematic review was performed in accordance with published guidelines. [11] [12] [13] [14] [15] The reporting of the review meets the criteria specified in the PRISMA guidance. 15 This is a systematic review consisting of analysis of previously reported data, and thus, ethics approval is not required.
Sources
A literature search was performed in electronic databases from inception till September 2015. We searched Embase, MEDLINE, CINAHL (current nursing and allied health literature) and Web of Science (grey literature) using combinations of relevant medical subject heading (MeSH) terms, keywords and word variants (Appendix S1). The reference lists of all included primary and review articles were examined to identify articles not captured by electronic searches. A comprehensive database collating all citations was constructed using Endnote 7 (Thomson Reuters). 16 
Study selection and data extraction
Two independent reviewers scrutinised the database (R.K.M. and A.B. partly in duplicate). The first stage of study selection was identifying articles based on title or abstract with translation of articles with abstracts not in English and removal of duplicates. In the second stage, all the citations that were thought to meet the predefined selection criterion were obtained. Following examination of full-text articles by the same reviewers, the following inclusion and exclusion decisions were made according to adherence to the following criteria:
• Population: pregnant women any health care setting, any level of risk.
• Tests: serum PAPP-A measured in the first trimester (<14 weeks)
• Reference standard/outcome: Birth weight, birth weight centile (population or customised), maternal (pre-eclampsia, pregnancy induced hypertension, gestational diabetes and abruption) and pregnancy outcomes (miscarriage, stillbirth and preterm delivery) and a composite adverse pregnancy outcome.
• Study design: observational test accuracy studies (cohorts and casecontrol prospective) allowing generation of 2 × 2 tables of accuracy. Case series <10 cases and case-control studies defined by reference standard outcome were excluded, these study designs have been shown to be associated with bias.
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No language restrictions were applied to the study. All manuscripts were carefully examined to identify overlapping populations. Where this was the case, most recent and complete manuscripts were selected. Data were extracted on study characteristics, quality assessment criteria and results for 2 × 2 tables (true positive, false positive, false negative and true negative) comparing the same threshold of PAPP-A with an individual outcome were obtained and entered into an Excel spreadsheet in duplicate by three reviewers (R.K.M., A. B. and P.D.). Discrepancies in data were resolved by a fourth reviewer (M.D.K.).
Study quality assessment
All studies meeting the predefined selection criteria were assessed for methodological and reporting quality, defined as confidence that the study design, conduct, analysis and reporting minimised any bias in the estimation of the association. Quality assessment was based on published guidelines for reporting of diagnostic accuracy studies (STARD) and methodological quality (QUADAS-2).
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The methodological quality items were adopted for the review question, and two authors independently judged each quality item. In case of discrepancies, consensus was reached by discussion.
Study quality was assessed in the domains of patient selection, index test, reference standard and flow and timing assessing risk of bias and applicability as per QUADAS-2. 20 For the population, consecutive or random recruitment of pregnant women was considered to be ideal. Prospective recruitment was considered to introduce less bias than retrospective recruitment. The description of the population was considered ideal if there was sufficient information about the pregnant women given to assign a level of obstetric risk, and ideally this risk level was stated by the authors in the study's methods.
The quality of performance and reporting of the index standard (PAPP-A) was assessed considering the processes reported for storage of the maternal serum sample if needed and the immunoassay analyser used in the lab to quantify the levels of serum PAPP-A. For the reference standard, any outcome relating to maternal, pregnancy or neonatal outcome was considered and information collected on method of determination of reference standard, execution and blinding.
Ideal study design were trials or cohort studies, case-control studies were only included when cases were not determined by reference standard/outcome as it has been shown that this type of study design can affect accuracy. 17 The assessment of quality is represented by a bar chart. No attempt was made to apply a quality score as this has been shown to have little validity, and quality was not an aspect for inclusion/exclusion of studies from meta-analysis instead an individual assessment was made, and this was used to inform investigations into heterogeneity in results and subgroup analysis where appropriate. 22 
Data synthesis and analysis
From the 2 × 2 tables the following were calculated with 95% confidence intervals (CI) for individual studies: Odds ratio (OR), sensitivity, specificity and the likelihood ratios (LRs). Results were pooled among groups of studies with similar characteristics, the same threshold for the index test and same reference standard definition and threshold. Studies also reported a composite adverse pregnancy outcome. These studies were included in a meta-analysis as long as it could be ensured that individuals were only counted once and that the individual outcomes of the composite were all of a similar magnitude and direction of effect across the studies. 23 The OR was selected as the summary statistic, as it represents the effect of the exposure on the odds in an unbiased fashion and enables the results of both case-control and cohort studies to be included and provides a measure of the test's prognostic ability. 24 Data were first displayed as forest plots of the OR and 95% CI to allow a visual inspection for heterogeneity. Statistical heterogeneity was assessed using the I 2 statistic
where I 2 > 50% is significant. 25 Random effects meta-analysis was used throughout in anticipation of significant clinical and statistical heterogeneity. Where there were zero cells within a table, a value of 0.5 was added to allow the calculation of log ORs and their variances for metaanalysis. 26 To explore for the presence of funnel plot asymmetry (small study effects), and thus potential publication bias, the Peters test was performed in each meta-analysis. 27 Where there was a moderate statistically significant association between PAPP-A and an outcome measure (defined as OR > 2 and 95% CI > 1) then sensitivity, specificity and LRs were considered, using data from the 2 × 2 tables. Predictive summary measures were synthesised using the bivariate random effects prediction model where there were at least four studies in the meta-analysis and univariate meta-analysis where this was not possible. 28 These measures assess the predictive ability of the test, that is, whether the test can accurately discriminate between those who do and those who do not have the adverse outcome (sensitivity and specificity) and by how much a positive or negative test result modifies the odds of a poor outcome (LRs). 12 Throughout p < 0.05 was considered to be statistical significance. All analyses were performed in STATA 10.0 (StataCorp, College Station, TX, USA) using the metan, metandi and metabias commands. [29] [30] [31] Univariate analyses were performed in Metadisc. 32 Figure 1 demonstrates the study selection process with 32 studies being included reporting on 175 240 pregnancies. 2, 5, All studies were performed on secondary or tertiary care settings in a low risk or unselected population. All were singleton pregnancies except five studies where it was not clear that multiples were excluded and all excluded fetuses with chromosomal or structural anomalies apart from six studies where again this was not clear. All studies were observational and non-interventional, 23 were a cohort design, 5 casecontrol, and in 4, the design was unclear. Case series were not included as there were sufficient larger studies (smallest n = 198). Recruitment was prospective in 13 studies, retrospective in 16 and unclear in 3. PAPP-A was performed between 8 and 14 weeks, and various thresholds were reported including centile cut-offs and multiples of the median (MoM). Outcomes included birth weight <10th centile in 17 studies, <5th centile in 15 studies or <3rd centile in third studies and >90th centile in 2 studies. Maternal outcomes assessed included 11 studies assessing pre-eclampsia, pregnancy induced hypertension in 6 studies, PTB <37 weeks in 22 studies and <34 and <32 weeks in two and three studies, respectively, gestational diabetes in 1 study, 4 studies assessed abruption and 4 studies pregnancy loss <24 weeks. Fetal outcomes assessed included eight studies looking at stillbirth >24 weeks. Six studies reported results for a composite adverse pregnancy outcome. Table S1 describes the characteristics of the included studies. Figure 2 displays the bar charts for methodological quality. The assessment of patient selection among the included studies showed that two publications were at high risk of bias because of being either a case-control study (Pawlowski 2013) or because exclusions were not clearly described (Spencer 2005) . 43, 59 Sensitivity analyses with these studies excluded demonstrated no significant difference to results. In the other three domains (index test, reference standard and flow and timing), all studies were judged overall to have a low risk of bias. When assessing applicability, one study was deemed to be at high risk as it included patients with early onset (second trimester) IUGR (Fox et al 2009) . 40 The overall high quality of the included studies meant that sub-group analysis based on quality was not required. Table 1 summarises the OR and 95% CI for all analyses. Forest plots for the main analyses are shown in Figure 3 . Where data were available to look at odds of an adverse outcome with PAPP-A <1st centile, this demonstrated increasing odds with decreasing PAPP-A ( Table 1) . Three of the analyses demonstrated significant heterogeneity (Birth weight <10th, PET and PTB). Inspection of the forest plots and table of characteristics could demonstrate no obvious cause for this. Peter's test revealed no significant evidence of small study effect across all analyses (range p = 0.39-p = 0.67) (Funnel plots shown for major meta-analyses in Figure S1 ) Predictive ability Table 1 also summarises the sensitivity, specificity, LRs and 95% CI for all analyses. Bivariate meta-analysis was possible for six test-outcome combinations: PAPP-A <10th centile and birth weight <10th; PAPP-A <5th centile and birth weight 10th and <5th centile, pre-eclampsia, PTB <37 weeks and stillbirth >24 weeks, and the hierarchical summary receiver operating characteristic curves are shown in Figure S2 . 
RESULTS

Prognostic association
Clinical interpretation
The predictive ability of PAPP-A can be converted to a probability of an adverse outcome for a low risk nulliparous woman (i.e. no known prior risk) in an unselected population with 8000 deliveries a year after a positive test (i.e. posterior test probability) using a nomogram (http://araw.mede.uic. edu/cgibin/testcalc.pl) ( Table 2) . Thus, following a PAPP-A in the first trimester less than <5th centile, a woman would have a 1 in 5.6 chance of an SGA baby (birth weight <10th centile) and a 1 in 3.7 of any adverse outcome. With lower levels of PAPP-A <1st centile the risks are considerably increased with a 1 in 3.6 chance of an SGA baby, 1 in 11 chance of pre-eclampsia, 1 in 3.7 chance of PTB (<37 weeks), 1 in 10 chance of late miscarriage and a 1 in 72 chance of stillbirth.
CONCLUSION Main findings
Low maternal serum PAPP-A in the first trimester has an association with adverse pregnancy outcome with a moderate association once levels are <5th centile for gestation and a stronger association <1st centile. The predictive values are poor; thus, although women with a low PAPP-A are at increased risk of an adverse outcome, the vast majority of these women will have a normal pregnancy outcome, and the majority of women with an adverse outcome will have a normal PAPP-A.
Strengths and limitations
The strength of this review and consequently the validity of the results for assessment of the prognostic and predictive value of PAPP-A lie in its methodology. This included complying with recommended techniques for quality assessment, 13, 20 performing and interpreting meta-analyses and reporting of our findings. 15, 28 Our search strategies were comprehensive and robust, evidenced by Peter's test demonstrating no evidence of small study bias. We have considered all aspects of test performance and displayed both prognostic and predictive ability of the test as well as demonstrating how the test would perform in a sample population.
Limitations within the review relate in the first instance to limitations within the included studies. There was significant statistical heterogeneity in some analyses that could not be accounted for when examining neither clinical characteristics nor study design and was thus unexplained. Within some analyses, there was a lack of data and thus for some bivariate meta-analysis could not be performed and for others test performance had to be assessed from a single study. We recognise that there are other variables that should be considered when assessing risk and that for the clinical interpretation we have assumed a background prevalence of the adverse outcome. It is not known how risk factors in obstetrics interact and how they modify risk in an individual. It is reasonable to assume however that in a woman with multiple risk factors, for example, previous SGA baby the risk will be higher than those discussed. One limitation in the methodology employed is the need to consider PAPP-A as a dichotomous variable, that is, categorisation using a threshold. This is a common technique in clinical research with dichotomization to simplify the analysis. This has limitations statistically as it can lead to a loss of power as much of the information is lost, classifying very similar factor values as different in opposite sides of the cut-off point and the concealment of a potential non-linear relationship between the outcome and the factor of interest. [63] [64] [65] One technique to overcome this is individual patient data meta-analysis, which uses original source data at the participant level, thus having many advantages such as being able to derive prognostic factor results directly, independent of study reporting and significance, and analyse continuous factors more appropriately.
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Interpretation Prognostic factor research is important as it allows us to potentially improve outcome for patients by identifying modifiable factors by either intervention, for example, delivery or by different management pathways, for example, surveillance. If treatments are available that may modify disease then prognostic factors may have a role in predicting differential treatment response. 68 Even if a prognostic factor is insufficient as a stand-alone test, it may still add some independent prognostic value over other prognostic factors, and used in a multivariable prognostic model to help provide absolute risk predictions for women based on their individual characteristics. 68 It is therefore imperative to robustly and systematically assess prognostic factors as has been performed in this review for PAPP-A.
Our results demonstrate evidence of associations between PAPP-A and adverse pregnancy outcomes. Future work should thus include individual patient data meta-analysis as previously discussed to allow assessment of PAPP-A as a continuous variable and its relationship with other prognostic markers available during the pregnancy; first trimester (e.g. crown rump length and nuchal translucency), second trimester (e.g. fetal biometry and uterine artery Doppler) and third trimester (e.g. placental biomarkers and placental morphology). [69] [70] [71] [72] [73] Any prognostic model developed would then require validation in external data sets. 74 At present in the UK practice, PAPP-A is only used as part of combined screening for Down syndrome and not as a biomarker for adverse outcome. Before any test (either individual or as a model) is introduced in this capacity into practice, there must be an assessment of the interventions that may be introduced, for example, increased surveillance or pharmacological, to ensure that screening in a population is justified and these interventions must be effective in the group identified as high risk via the test or model. At present, although aspirin has been suggested as a possible intervention in certain groups (e.g. those at high risk of pre-eclampsia based on previous history), there is no evidence for the effectiveness in a group selected by either PAPP-A as a stand-alone test or a model including PAPP-A. This allows the clinical effectiveness in reducing the adverse outcome to be assessed. However, the results of this systematic review allow appropriate counselling of women who have had PAPP-A assessed as part of Down syndrome screening.
Low maternal serum PAPP-A in the first trimester has an association with adverse pregnancy outcome particularly if levels are very low (<1st centile). It must be recognised that for the individual, predictive values are poor, and the majority of adverse outcomes will occur in the group without an abnormally low PAPP-A. There are also no proven interventions in this group. Therefore, future research is required to develop robust and accurate prediction models and effective interventions that can allow modern day obstetrics to practice truly stratified medicine. 75 
Ethics approval
This is a systematic review consisting of analysis of previously reported data and thus ethics approval is not required. 
WHAT'S ALREADY KNOWN ON THIS TOPIC?
• Low levels of PAPP-A are associated with small for gestational age and pre-eclampsia.
WHAT DOES THIS STUDY ADD?
• Low maternal serum PAPP-A in the first trimester has an association with adverse pregnancy outcome particularly if levels are very low (<1st centile).
• For an individual prediction is poor, thus, the majority of adverse outcomes will occur in the group without an abnormally low PAPP-A.
• Future research is required to develop prediction models and effective interventions.
